Benchmark analyst Mike Hickey said Tilray reported "strong" Q3 sales even though the company did not recognize sales from recreational cannabis use in the quarter. Recreational use experienced a slow start, primarily due to the timing of licenses, distribution and retail infrastructure, as expected, said Hickey, who adds that there "appears to be exceedingly strong demand" from Canadians. He has raised his Q4 sales forecast based on increased production and presumed ongoing strong consumer demand and keeps a Buy rating on Tilray with a $200 price target.